DOCSLIB.ORG

Therapeutic Efficacy of Small Molecules to Treat Channelopathies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Therapeutic Efficacy of Small Molecules to Treat Channelopathies Therapeutic efficacy of small molecules to treat channelopathies A thesis submitted to The University of Manchester for the degree of Doctor of Philosophy in the Faculty of Biology, Medicine and Health 2019 Jingshu Liu School of Biological Sciences Division of Evolution and Genomic Sciences Table of Contents List of Figures ................................................................................................................... 8 List of Tables ................................................................................................................... 11 Abstract ........................................................................................................................... 12 Declaration ...................................................................................................................... 13 Copyright statement ........................................................................................................ 13 Acknowledgement ........................................................................................................... 14 Abbreviations .................................................................................................................. 15 1 Chapter 1: Introduction ............................................................................................ 19 1.1 Human eye ........................................................................................................ 19 1.1.1 Retina ............................................................................................................ 20 1.1.2 Neural retina ................................................................................................. 20 1.1.2.1 The retinal pigment epithelium (RPE) .................................................. 21 1.1.3 Inherited retinal disorders (IRDs) ................................................................. 21 1.1.3.1 Genetics of IRDs ................................................................................... 22 1.1.3.2 Therapeutic strategies for IRDs ............................................................. 22 1.1.3.2.1 Gene therapy ................................................................................... 23 1.1.3.2.2 Cell-based therapy ........................................................................... 23 1.1.3.2.3 Retinal prostheses ............................................................................ 24 1.1.3.2.4 Pharmacotherapy ............................................................................. 24 1.2 Bestrophin-1 ..................................................................................................... 25 1.2.1 Human BEST1 gene ...................................................................................... 25 1.2.2 Structure of bestrophin-1 .............................................................................. 25 1.2.3 Function of bestrophin-1 ............................................................................... 29 1.2.4 Bestrophinopathy .......................................................................................... 29 1.2.4.1 Best vitelliform macular dystrophy (BVMD) ....................................... 30 1.2.4.1.1 Phenotypes and genotypes of BVMD ............................................. 30 1.2.4.1.2 Features of BVMD-related bestrophin-1 ......................................... 31 1 1.2.4.2 Autosomal recessive bestrophinopathy (ARB) ..................................... 31 1.2.4.2.1 Phenotypes and genotypes of ARB ................................................. 31 1.2.4.2.2 Features of ARB-related bestrophin-1 ............................................ 32 1.2.4.3 Autosomal dominant vitreoretinochoroidopathy (ADVIRC) ................ 33 1.2.4.3.1 Phenotypes and genotypes of ADVIRC .......................................... 33 1.2.4.3.2 Features of ADVIRC-related bestrophin-1 ..................................... 33 1.2.5 Cell models of bestrophinopathy .................................................................. 34 1.2.6 Animal models of bestrophinopathy ............................................................. 34 1.2.6.1 Rat model ............................................................................................... 34 1.2.6.2 Mouse model ......................................................................................... 35 1.2.6.3 Canine model ......................................................................................... 36 1.3 Protein folding and proteostasis ....................................................................... 36 1.3.1 Protein folding in the endoplasmic reticulum (ER) ...................................... 37 1.3.1.1 Translocation ......................................................................................... 37 1.3.1.2 Molecular chaperones ............................................................................ 38 1.3.1.3 Disulfide bond formation ...................................................................... 39 1.3.1.4 N-linked glycosylation .......................................................................... 39 1.3.1.5 ER to Golgi export ................................................................................. 41 1.3.2 Protein modification in the Golgi apparatus ................................................. 41 1.3.3 Protein quality control system ...................................................................... 42 1.3.3.1 Unfolded protein response (UPR) ......................................................... 42 1.3.3.2 ER associated degradation (ERAD) ...................................................... 43 1.3.3.3 Protein quality control beyond the ER .................................................. 45 1.3.3.4 Autophagy ............................................................................................. 45 1.3.4 Protein misfolding diseases .......................................................................... 46 1.3.5 Small molecule treatment for protein misfolding diseases ........................... 47 2 Chapter 2: Materials and Methods ........................................................................... 51 2.1 Suppliers ........................................................................................................... 51 2 2.2 Antibodies ......................................................................................................... 51 2.3 Buffers and solutions ........................................................................................ 52 2.4 Bacteriological procedures ............................................................................... 53 2.4.1 Preparation of Luria Bertani (LB) broth and LB agar .................................. 53 2.4.2 Bacterial culture growth ................................................................................ 53 2.5 Nucleic acid procedures ................................................................................... 54 2.5.1 RNA extraction ............................................................................................. 54 2.5.2 Reverse transcription polymerase chain reaction (RT-PCR) ........................ 54 2.5.3 Real-Time quantitative PCR (qRT-PCR) ..................................................... 55 2.5.4 Plasmid DNA preparation ............................................................................. 56 2.5.5 Restriction enzyme digests ........................................................................... 56 2.5.6 DNA purification .......................................................................................... 56 2.5.7 Agarose gel electrophoresis .......................................................................... 57 2.5.8 Ethanol precipitation of DNA ....................................................................... 57 2.5.9 Site directed mutagenesis (SDM) ................................................................. 57 2.5.10 DNA sequencing ....................................................................................... 58 2.6 Tissue culture procedures ................................................................................. 59 2.6.1 Cell Culture ................................................................................................... 59 2.6.1.1 Human embryonic kidney 293T (HEK293T) cell ................................. 59 2.6.1.2 Madin-Darby canine kidney type II (MDCKII) cell ............................. 59 2.6.1.3 Chinese hamster ovary (CHO-K1) cell ................................................. 60 2.6.1.4 Human iPSC-retinal pigment epithelium (iPSC-RPE) cells ................. 60 2.6.1.4.1 Generation of iPSC .......................................................................... 60 2.6.1.4.2 Differentiation of iPSC into RPE .................................................... 61 2.6.2 Transient transfection ................................................................................... 62 2.6.2.1 HEK293T cells ...................................................................................... 62 2.6.2.2 CHO-K1 cells ........................................................................................ 63 2.6.3 Stable transfection ......................................................................................... 63 3 2.6.3.1 Stable transfection of BEST1 in MDCKII cells .................................... 64 2.6.3.2 Stable transfection of EYFP H148Q/I152L in MDCKII cells .............. 65 2.6.4
Load more

Recommended publications
  • CLCN5 Gene Chloride Voltage-Gated Channel 5
    CLCN5 gene chloride voltage-gated channel 5 Normal Function The CLCN5 gene provides instructions for making a protein called ClC-5 that transports charged atoms (ions) across cell membranes. Specifically, ClC-5 exchanges negatively charged atoms of chlorine (chloride ions) for positively charged atoms of hydrogen ( protons or hydrogen ions). Based on this function, ClC-5 is known as a H+/Cl- exchanger. ClC-5 is found primarily in the kidneys, particularly in structures called proximal tubules. These structures help to reabsorb nutrients, water, and other materials that have been filtered from the bloodstream. The kidneys reabsorb needed materials into the blood and excrete everything else into the urine. Within proximal tubule cells, ClC-5 is embedded in specialized compartments called endosomes. Endosomes are formed at the cell surface to carry proteins and other molecules to their destinations within the cell. ClC-5 transports hydrogen ions into endosomes and chloride ions out, which helps these compartments maintain the proper acidity level (pH). Endosomal pH levels must be tightly regulated for proximal tubule cells to function properly. Health Conditions Related to Genetic Changes Dent disease About 150 mutations in the CLCN5 gene have been found to cause Dent disease 1, a chronic kidney disorder that can cause kidney failure. Most of the mutations lead to the production of an abnormally short, nonfunctional version of ClC-5 or prevent cells from producing any of this protein. A loss of ClC-5 alters the regulation of endosomal pH, which disrupts the overall function of proximal tubule cells and prevents them from reabsorbing proteins and other materials into the bloodstream.
    [Show full text]
  • K+ Channel Modulators Product ID Product Name Description D3209 Diclofenac Sodium Salt NSAID; COX-1/2 Inhibitor, Potential K+ Channel Modulator
    K+ Channel Modulators Product ID Product Name Description D3209 Diclofenac Sodium Salt NSAID; COX-1/2 inhibitor, potential K+ channel modulator. G4597 18β-Glycyrrhetinic Acid Triterpene glycoside found in Glycyrrhiza; 15-HPGDH inhibitor, hERG and KCNA3/Kv1.3 K+ channel blocker. A4440 Allicin Organosulfur found in garlic, binds DNA; inwardly rectifying K+ channel activator, L-type Ca2+ channel blocker. P6852 Propafenone Hydrochloride β-adrenergic antagonist, Kv1.4 and K2P2 K+ channel blocker. P2817 Phentolamine Hydrochloride ATP-sensitive K+ channel activator, α-adrenergic antagonist. P2818 Phentolamine Methanesulfonate ATP-sensitive K+ channel activator, α-adrenergic antagonist. T7056 Troglitazone Thiazolidinedione; PPARγ agonist, ATP-sensitive K+ channel blocker. G3556 Ginsenoside Rg3 Triterpene saponin found in species of Panax; γ2 GABA-A agonist, Kv7.1 K+ channel activator, α10 nAChR antagonist. P6958 Protopanaxatriol Triterpene sapogenin found in species of Panax; GABA-A/C antagonist, slow-activating delayed rectifier K+ channel blocker. V3355 Vindoline Semi-synthetic vinca alkaloid found in Catharanthus; Kv2.1 K+ channel blocker and H+/K+ ATPase inhibitor. A5037 Amiodarone Hydrochloride Voltage-gated Na+, Ca2+, K+ channel blocker, α/β-adrenergic antagonist, FIASMA. B8262 Bupivacaine Hydrochloride Monohydrate Amino amide; voltage-gated Na+, BK/SK, Kv1, Kv3, TASK-2 K+ channel inhibitor. C0270 Carbamazepine GABA potentiator, voltage-gated Na+ and ATP-sensitive K+ channel blocker. C9711 Cyclovirobuxine D Found in Buxus; hERG K+ channel inhibitor. D5649 Domperidone D2/3 antagonist, hERG K+ channel blocker. G4535 Glimepiride Sulfonylurea; ATP-sensitive K+ channel blocker. G4634 Glipizide Sulfonylurea; ATP-sensitive K+ channel blocker. I5034 Imiquimod Imidazoquinoline nucleoside analog; TLR-7/8 agonist, KCNA1/Kv1.1 and KCNA2/Kv1.2 K+ channel partial agonist, TREK-1/ K2P2 and TRAAK/K2P4 K+ channel blocker.
    [Show full text]
  • Hereditary Kidney Disorders
    A. Stavljenić-Rukavina Hereditary kidney disorders How to Cite this article: Hereditary Kidney Disorders- eJIFCC 20/01 2009 http://www.ifcc.org 5. HEREDITARY KIDNEY DISORDERS Ana Stavljenić-Rukavina 5.1 Introduction Hereditary kidney disorders represent significant risk for the development of end stage renal desease (ESRD). Most of them are recognized in childhood, or prenataly particularly those phenotypicaly expressed as anomalies on ultrasound examination (US) during pregnancy. They represent almost 50% of all fetal malformations detected by US (1). Furthermore many of urinary tract malformations are associated with renal dysplasia which leeds to renal failure. Recent advances in molecular genetics have made a great impact on better understanding of underlying molecular mechanisms in different kidney and urinary tract disorders found in childhood or adults. Even some of clinical syndromes were not recognized earlier as genetic one. In monogenic kidney diseases gene mutations have been identified for Alport syndrome and thin basement membrane disease, autosomal dominant polycystic kidney disease, and tubular transporter disorders. There is evident progress in studies of polygenic renal disorders as glomerulopathies and diabetic nephropathy. The expanded knowledge on renal physiology and pathophysiology by analyzing the phenotypes caused by defected genes might gain to earlier diagnosis and provide new diagnostic and prognostic tool. The global increasing number of patients with ESRD urges the identification of molecular pathways involved in renal pathophysiology in order to serve as targets for either prevention or intervention. Molecular genetics nowadays possess significant tools that can be used to identify genes involved in renal disease including gene expression arrays, linkage analysis and association studies.
    [Show full text]
  • The Chondrocyte Channelome: a Novel Ion Channel Candidate in the Pathogenesis of Pectus Deformities
    Old Dominion University ODU Digital Commons Biological Sciences Theses & Dissertations Biological Sciences Summer 2017 The Chondrocyte Channelome: A Novel Ion Channel Candidate in the Pathogenesis of Pectus Deformities Anthony J. Asmar Old Dominion University, [email protected] Follow this and additional works at: https://digitalcommons.odu.edu/biology_etds Part of the Biology Commons, Molecular Biology Commons, and the Physiology Commons Recommended Citation Asmar, Anthony J.. "The Chondrocyte Channelome: A Novel Ion Channel Candidate in the Pathogenesis of Pectus Deformities" (2017). Doctor of Philosophy (PhD), Dissertation, Biological Sciences, Old Dominion University, DOI: 10.25777/pyha-7838 https://digitalcommons.odu.edu/biology_etds/19 This Dissertation is brought to you for free and open access by the Biological Sciences at ODU Digital Commons. It has been accepted for inclusion in Biological Sciences Theses & Dissertations by an authorized administrator of ODU Digital Commons. For more information, please contact [email protected]. THE CHONDROCYTE CHANNELOME: A NOVEL ION CHANNEL CANDIDATE IN THE PATHOGENESIS OF PECTUS DEFORMITIES by Anthony J. Asmar B.S. Biology May 2010, Virginia Polytechnic Institute M.S. Biology May 2013, Old Dominion University A Dissertation Submitted to the Faculty of Old Dominion University in Partial Fulfillment of the Requirements for the Degree of DOCTOR OF PHILOSOPHY BIOMEDICAL SCIENCES OLD DOMINION UNIVERSITY August 2017 Approved by: Christopher Osgood (Co-Director) Michael Stacey (Co-Director) Lesley Greene (Member) Andrei Pakhomov (Member) Jing He (Member) ABSTRACT THE CHONDROCYTE CHANNELOME: A NOVEL ION CHANNEL CANDIDATE IN THE PATHOGENESIS OF PECTUS DEFORMITIES Anthony J. Asmar Old Dominion University, 2017 Co-Directors: Dr. Christopher Osgood Dr. Michael Stacey Costal cartilage is a type of rod-like hyaline cartilage connecting the ribs to the sternum.
    [Show full text]
  • Drugs, Herg and Sudden Death A.M
    Cell Calcium 35 (2004) 543–547 Drugs, hERG and sudden death A.M. Brown a,b,∗ a MetroHealth Campus, Case Western Reserve University, Cleveland, OH 44128, USA b ChanTest, Inc., 14656 Neo Parkway, Cleveland, OH 44128, USA Received 1 December 2003; accepted 12 January 2004 Abstract Early recognition of potential QT/TdP liability is now an essential component of the drug discovery/drug development program. The hERG assay is an indispensable step and a high-quality assay must accompany any investigational new drug (IND) application. While it is the gold standard at present, the hERG assay is too labor-intensive and too low throughput to be used as a screen early in the discovery/development process. A variety of indirect high throughput screens have been used. © 2004 Elsevier Ltd. All rights reserved. Keywords: Screens; Throughput; hERG; QT; Sudden death Sudden cardiac death due to non-cardiac drugs is the ma- fexofenadine, the active metabolite for which terfenadine is jor safety issue presently facing the pharmaceutical industry a pro-drug, became available. and the agencies that regulate it. In recent years, several TdP is linked to defective repolarization and prolongation blockbuster drugs such as terfenadine (Seldane), cisapride of the QT interval of the EKG; at the cellular level the (Propulsid), grepafloxacin (Raxar) and terodiline have been duration of the cardiac action potential (APD) is prolonged. withdrawn from major markets, other drugs such as sertin- The major membrane currents that might be involved are dole (Serlect) have been withdrawn prior to marketing and shown in Fig. 1. still others such as ziprasidone (Zeldox) have undergone In 1993, Woosley’s lab showed that terfenadine blocked + severe labeling restrictions.
    [Show full text]
  • Atomistic Insights of Calmodulin Gating of Complete Ion Channels
    International Journal of Molecular Sciences Review Atomistic Insights of Calmodulin Gating of Complete Ion Channels Eider Núñez y, Arantza Muguruza-Montero y and Alvaro Villarroel * Biofisika Institute (CSIC, UPV/EHU), University of the Basque Country, 48940 Leioa, Spain; [email protected] (E.N.); [email protected] (A.M.-M.) * Correspondence: [email protected]; Tel.: +34-9460-13225 These authors contribute equally to this work. y Received: 18 December 2019; Accepted: 12 February 2020; Published: 14 February 2020 Abstract: Intracellular calcium is essential for many physiological processes, from neuronal signaling and exocytosis to muscle contraction and bone formation. Ca2+ signaling from the extracellular medium depends both on membrane potential, especially controlled by ion channels selective to K+, and direct permeation of this cation through specialized channels. Calmodulin (CaM), through direct binding to these proteins, participates in setting the membrane potential and the overall permeability to Ca2+. Over the past years many structures of complete channels in complex with CaM at near atomic resolution have been resolved. In combination with mutagenesis-function, structural information of individual domains and functional studies, different mechanisms employed by CaM to control channel gating are starting to be understood at atomic detail. Here, new insights regarding four types of tetrameric channels with six transmembrane (6TM) architecture, Eag1, SK2/SK4, TRPV5/TRPV6 and KCNQ1–5, and its regulation by CaM are described structurally. Different CaM regions, N-lobe, C-lobe and EF3/EF4-linker play prominent signaling roles in different complexes, emerging the realization of crucial non-canonical interactions between CaM and its target that are only evidenced in the full-channel structure.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Transcriptomic and Proteomic Profiling Provides Insight Into
    BASIC RESEARCH www.jasn.org Transcriptomic and Proteomic Profiling Provides Insight into Mesangial Cell Function in IgA Nephropathy † † ‡ Peidi Liu,* Emelie Lassén,* Viji Nair, Celine C. Berthier, Miyuki Suguro, Carina Sihlbom,§ † | † Matthias Kretzler, Christer Betsholtz, ¶ Börje Haraldsson,* Wenjun Ju, Kerstin Ebefors,* and Jenny Nyström* *Department of Physiology, Institute of Neuroscience and Physiology, §Proteomics Core Facility at University of Gothenburg, University of Gothenburg, Gothenburg, Sweden; †Division of Nephrology, Department of Internal Medicine and Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan; ‡Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan; |Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden; and ¶Integrated Cardio Metabolic Centre, Karolinska Institutet Novum, Huddinge, Sweden ABSTRACT IgA nephropathy (IgAN), the most common GN worldwide, is characterized by circulating galactose-deficient IgA (gd-IgA) that forms immune complexes. The immune complexes are deposited in the glomerular mesangium, leading to inflammation and loss of renal function, but the complete pathophysiology of the disease is not understood. Using an integrated global transcriptomic and proteomic profiling approach, we investigated the role of the mesangium in the onset and progression of IgAN. Global gene expression was investigated by microarray analysis of the glomerular compartment of renal biopsy specimens from patients with IgAN (n=19) and controls (n=22). Using curated glomerular cell type–specific genes from the published literature, we found differential expression of a much higher percentage of mesangial cell–positive standard genes than podocyte-positive standard genes in IgAN. Principal coordinate analysis of expression data revealed clear separation of patient and control samples on the basis of mesangial but not podocyte cell–positive standard genes.
    [Show full text]
  • Epileptic Mechanisms Shared by Alzheimer's Disease
    International Journal of Molecular Sciences Review Epileptic Mechanisms Shared by Alzheimer’s Disease: Viewed via the Unique Lens of Genetic Epilepsy Jing-Qiong Kang 1,2 1 Department of Neurology & Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232-8552, USA; [email protected]; Tel.: +1-615-936-8399; Fax: +1-615-322-5517 2 Vanderbilt Kennedy Center of Human Development, Vanderbilt Brain Institute, Vanderbilt University, Nashville, TN 37232-8522, USA Abstract: Our recent work on genetic epilepsy (GE) has identified common mechanisms between GE and neurodegenerative diseases including Alzheimer’s disease (AD). Although both disorders are seemingly unrelated and occur at opposite ends of the age spectrum, it is likely there are shared mechanisms and studies on GE could provide unique insights into AD pathogenesis. Neurodegen- erative diseases are typically late-onset disorders, but the underlying pathology may have already occurred long before the clinical symptoms emerge. Pathophysiology in the early phase of these diseases is understudied but critical for developing mechanism-based treatment. In AD, increased seizure susceptibility and silent epileptiform activity due to disrupted excitatory/inhibitory (E/I) balance has been identified much earlier than cognition deficit. Increased epileptiform activity is likely a main pathology in the early phase that directly contributes to impaired cognition. It is an enormous challenge to model the early phase of pathology with conventional AD mouse models due to the chronic disease course, let alone the complex interplay between subclinical nonconvulsive epileptiform activity, AD pathology, and cognition deficit. We have extensively studied GE, especially with gene mutations that affect the GABA pathway such as mutations in GABAA receptors and GABA transporter Citation: Kang, J.-Q.
    [Show full text]
  • Ion Channels 3 1
    r r r Cell Signalling Biology Michael J. Berridge Module 3 Ion Channels 3 1 Module 3 Ion Channels Synopsis Ion channels have two main signalling functions: either they can generate second messengers or they can function as effectors by responding to such messengers. Their role in signal generation is mainly centred on the Ca2 + signalling pathway, which has a large number of Ca2+ entry channels and internal Ca2+ release channels, both of which contribute to the generation of Ca2 + signals. Ion channels are also important effectors in that they mediate the action of different intracellular signalling pathways. There are a large number of K+ channels and many of these function in different + aspects of cell signalling. The voltage-dependent K (KV) channels regulate membrane potential and + excitability. The inward rectifier K (Kir) channel family has a number of important groups of channels + + such as the G protein-gated inward rectifier K (GIRK) channels and the ATP-sensitive K (KATP) + + channels. The two-pore domain K (K2P) channels are responsible for the large background K current. Some of the actions of Ca2 + are carried out by Ca2+-sensitive K+ channels and Ca2+-sensitive Cl − channels. The latter are members of a large group of chloride channels and transporters with multiple functions. There is a large family of ATP-binding cassette (ABC) transporters some of which have a signalling role in that they extrude signalling components from the cell. One of the ABC transporters is the cystic − − fibrosis transmembrane conductance regulator (CFTR) that conducts anions (Cl and HCO3 )and contributes to the osmotic gradient for the parallel flow of water in various transporting epithelia.
    [Show full text]
  • X-Linked Diseases: Susceptible Females
    REVIEW ARTICLE X-linked diseases: susceptible females Barbara R. Migeon, MD 1 The role of X-inactivation is often ignored as a prime cause of sex data include reasons why women are often protected from the differences in disease. Yet, the way males and females express their deleterious variants carried on their X chromosome, and the factors X-linked genes has a major role in the dissimilar phenotypes that that render women susceptible in some instances. underlie many rare and common disorders, such as intellectual deficiency, epilepsy, congenital abnormalities, and diseases of the Genetics in Medicine (2020) 22:1156–1174; https://doi.org/10.1038/s41436- heart, blood, skin, muscle, and bones. Summarized here are many 020-0779-4 examples of the different presentations in males and females. Other INTRODUCTION SEX DIFFERENCES ARE DUE TO X-INACTIVATION Sex differences in human disease are usually attributed to The sex differences in the effect of X-linked pathologic variants sex specific life experiences, and sex hormones that is due to our method of X chromosome dosage compensation, influence the function of susceptible genes throughout the called X-inactivation;9 humans and most placental mammals – genome.1 5 Such factors do account for some dissimilarities. compensate for the sex difference in number of X chromosomes However, a major cause of sex-determined expression of (that is, XX females versus XY males) by transcribing only one disease has to do with differences in how males and females of the two female X chromosomes. X-inactivation silences all X transcribe their gene-rich human X chromosomes, which is chromosomes but one; therefore, both males and females have a often underappreciated as a cause of sex differences in single active X.10,11 disease.6 Males are the usual ones affected by X-linked For 46 XY males, that X is the only one they have; it always pathogenic variants.6 Females are biologically superior; a comes from their mother, as fathers contribute their Y female usually has no disease, or much less severe disease chromosome.
    [Show full text]
  • SUPPLEMENTARY MATERIAL Effect of Next
    SUPPLEMENTARY MATERIAL Effect of Next-Generation Exome Sequencing Depth for Discovery of Diagnostic Variants KKyung Kim1,2,3†, Moon-Woo Seong4†, Won-Hyong Chung3, Sung Sup Park4, Sangseob Leem1, Won Park5,6, Jihyun Kim1,2, KiYoung Lee1,2*‡, Rae Woong Park1,2* and Namshin Kim5,6** 1Department of Biomedical Informatics, Ajou University School of Medicine, Suwon 443-749, Korea 2Department of Biomedical Science, Graduate School, Ajou University, Suwon 443-749, Korea, 3Korean Bioinformation Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 305-806, Korea, 4Department of Laboratory Medicine, Seoul National University Hospital College of Medicine, Seoul 110-799, Korea, 5Department of Functional Genomics, Korea University of Science and Technology, Daejeon 305-806, Korea, 6Epigenomics Research Center, Genome Institute, Korea Research Institute of Bioscience and Biotechnology, Daejeon 305-806, Korea http//www. genominfo.org/src/sm/gni-13-31-s001.pdf Supplementary Table 1. List of diagnostic genes Gene Symbol Description Associated diseases ABCB11 ATP-binding cassette, sub-family B (MDR/TAP), member 11 Intrahepatic cholestasis ABCD1 ATP-binding cassette, sub-family D (ALD), member 1 Adrenoleukodystrophy ACVR1 Activin A receptor, type I Fibrodysplasia ossificans progressiva AGL Amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase Glycogen storage disease ALB Albumin Analbuminaemia APC Adenomatous polyposis coli Adenomatous polyposis coli APOE Apolipoprotein E Apolipoprotein E deficiency AR Androgen receptor Androgen insensitivity
    [Show full text]